- Dr. Samantha Nutt has Been
Elected to Covalon's Board
- Mr. Martin Goldfarb has Retired
from Covalon's Board
MISSISSAUGA, ON, March 10,
2022 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, today announced that Dr. Samantha Nutt has been elected a Director
subject to TSX approval and Mr. Martin
Goldfarb has retired as a Director of the Covalon Board.
Dr. Samantha Nutt (MD, MSc, CCFP,
FCPC, C.M.) is a medical doctor, best-selling author, and
award-winning humanitarian. As Founder and President of War Child
Canada and War Child USA, Dr.
Nutt has worked with children and their families at the frontline
of many of the world's major crises. With a career that has spanned
more than two decades and dozens of conflict zones, her
international work has benefited millions of war-affected children
globally.
Dr. Nutt has been appointed to the Order of Canada and is a recipient of the Order of
Ontario. She graduated summa cum laude from McMaster University, earned an M.Sc. in Public
Health with distinction from the London School of Hygiene and
Tropical Medicine, and holds a Fellowship in Community
Medicine/Public Health (FRCPC) from the Royal College of Physicians
and Surgeons of Canada. She is further certified by the
College of Family Practice (CCFP) and completed a
sub-specialization in women's health through the University of Toronto as a Women's Health Scholar.
Dr. Nutt is the recipient of numerous honorary doctorates from
universities in Canada and the
U.S.A. She is a staff physician at Women's College Hospital
in Toronto and an Assistant
Professor of Medicine at the University of
Toronto.
"We are delighted that Dr. Nutt has joined Covalon's Board,"
said Brian Pedlar, Chief Executive
Officer. "Her specialized medical expertise and extraordinary
philanthropic achievements will be a tremendous asset to
Covalon."
The Company also announced that Mr. Martin Goldfarb has retired from Covalon's
Board.
Amir Boloor, Chair of Covalon's
Board of Directors, said, "We are extremely grateful for Marty's
numerous contributions as a Director, supporter, and mentor to
Covalon for many years. Marty has continuously pushed Covalon to
improve and is one of the key reasons Covalon succeeded in its
turnaround that saw the Company finish 2021 with a clean balance
sheet, no debt, and $25 million in
cash. Marty's guidance, knowledge, and passion helped Covalon
navigate through a challenging time during the Covid-19 pandemic.
Marty is a legend for his many business, government, private
equity, and philanthropic accomplishments which have resulted in
many public recognitions including the Order of Canada. Covalon will forever be grateful for
his many contributions to the Company."
About Covalon
Covalon Technologies Ltd. is a
researcher, developer, manufacturer, and marketer of
patent-protected medical products that improve patient outcomes and
save lives in the areas of advanced wound care, infection
management and surgical procedures. Covalon leverages its patented
medical technology platforms and expertise in two ways: (i) by
developing products that are sold under Covalon's name; and (ii) by
developing and commercializing medical products for other medical
companies under development and license contracts. The Company is
listed on the TSX Venture Exchange, having the symbol COV and
trades on the OTCQX Market under the symbol CVALF. To learn more
about Covalon, visit our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results, the
impact and timing of COVID-19 on operating activities and market
conditions, and other risks, any of which could cause
results, performance, or achievements to differ materially from the
results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific
to the Company. Investors should consult the Company's ongoing
quarterly filings for additional information on risks and
uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter
any forward-looking statements whether as a result of new
information, further events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-announces-changes-to-its-board-of-directors-301499650.html
SOURCE Covalon Technologies Ltd.